CAMBRIDGE EPIGENETIX
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, no... w one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.
CAMBRIDGE EPIGENETIX
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2012-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.cambridge-epigenetix.com
Total Employee:
51+
Status:
Active
Contact:
+44 1223 800700
Email Addresses:
[email protected]
Total Funding:
155.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Foundation Medicine
Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.
Metabolomic Diagnostics
Metabolomic Diagnostics specializes in the development of novel biomarker based diagnostic solutions for complex diseases
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Redcliffe Labs
Redcliffe is a one-stop diagnostic platform offering a wide selection of tests to choose from and delivering care closer to the customer.
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Advisors List
Current Employees Featured
Founder
Investors List
New Science Ventures
New Science Ventures investment in Series D - Cambridge Epigenetix
Temasek Holdings
Temasek Holdings investment in Series D - Cambridge Epigenetix
Third Point
Third Point investment in Series D - Cambridge Epigenetix
Sequoia Capital
Sequoia Capital investment in Series D - Cambridge Epigenetix
Ahren Innovation Capital
Ahren Innovation Capital investment in Series D - Cambridge Epigenetix
GV
GV investment in Series D - Cambridge Epigenetix
New Science Ventures
New Science Ventures investment in Series C - Cambridge Epigenetix
GV
GV investment in Series C - Cambridge Epigenetix
Ahren Innovation Capital
Ahren Innovation Capital investment in Series C - Cambridge Epigenetix
DNA Capital
DNA Capital investment in Series C - Cambridge Epigenetix
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-14 | Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer |
Official Site Inspections
http://www.cambridge-epigenetix.com Semrush global rank: 5 M Semrush visits lastest month: 1.68 K
- Host name: 83.0.153.160.host.secureserver.net
- IP address: 160.153.0.83
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
